Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
Leiming Xia,1,2,* Wei Qian,3,* Mingzhen Yang,3,4 Qingsheng Li,4 Fei Liu,5 Yanyan Xie4 1Department of Hematology, The Third Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 2Department of Hematology, Hefei Binhu Hospital, Hefei, People’s Republi...
Main Authors: | Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-09-01
|
Series: | OncoTargets and Therapy |
Online Access: | https://www.dovepress.com/comparison-of-the-utility-and-applicability-of-the-sokal-hasford-and-e-peer-reviewed-article-OTT |
Similar Items
-
A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers
by: Swapan Kumar Sinha, et al.
Published: (2013-01-01) -
Comparison of the applicability of Hasford score and European Treatment and Outcome Study score in Indian patients with chronic phase chronic myeloid leukemia on imatinib therapy
by: Neha Chopra Narang, et al.
Published: (2017-01-01) -
Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study
by: Yang X, et al.
Published: (2020-02-01) -
Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
by: Sunita Chhikara, et al.
Published: (2018-01-01) -
Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months
by: Andy Purnomo, et al.
Published: (2019-09-01)